title: [Tuberculosis: a current problem].
abstract: Tuberculosis is a public health problem. If the current trends continue, is expected to arrive to 10.2 million of new cases in 2005. There are three studies accomplished in 1995 in Mexican patients. The results show important difficulty in the application and the follow-up of the program of control of the tuberculosis, what has caused accumulation of chronic cases, moderate rate of primary resistance and alarming levels of primary and secondary multiresistance (23%). Mechanism of protective immunity against mycobacterium tuberculosis (MTB) in humans have not been clarified. Different subpopulations of lymphocytes CD4, CD8 and other populations as well as macrophages, and monocytes, have an important role. In industrialized countries, the managing of the MDRTB is based on the use of individualized treatments with second line drugs according to susceptibility test, however the foregoing has not been possible to apply it middle or low income countries. WHO has launches the initiative "DOTS plus" that consist in the administration of a standarized regimen on the basis of epidemiology of resistance in the country or region.
authors.affiliation: Instituto Nacional de Enfermedades Respiratorias, Calzada de Tlalpan 4502, Colonia Sección XVI, Tlalpan, D.F. México.
authors.forename: Jaime
authors.initials: J
authors.lastname: Villalba-Caloca
authors.forename: María de Lourdes
authors.initials: Mde L
authors.lastname: García-García
authors.forename: José
authors.initials: J
authors.lastname: Sifuentes-Osornio
authors.forename: Eduardo
authors.initials: E
authors.lastname: Sada-Díaz
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Salazar-Lezama
mesh_terms: D004352:Drug Resistance, Microbial; D006801:Humans; D008800:Mexico; D017720:Molecular Epidemiology; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology